Terms of Use
Rules for using the PrimeIdea Ventures website — educational content, market risks, and clear role boundaries. Guided by Partha Shah, SEBI Registered Research Analyst INH000017815.

These terms apply to use of the website. Registration, Investor Charter, grievance, and risk details live on Regulatory Disclosures.
By using primeidea.in you agree to these terms. If you do not agree, please do not use the site. Content is provided for information and education about research-led portfolio review and related services.
PrimeIdea Ventures is a Vadodara-based research-led wealth management and portfolio review firm serving investors across Gujarat and India, with a research process guided by Partha Shah, SEBI Registered Research Analyst INH000017815. PrimeIdea does not present itself as a SEBI Registered Investment Adviser unless separately registered.
Website content, calculators, comparisons, and articles are educational and illustrative. They are not personalised investment advice, a solicitation to buy or sell securities, or a promise of returns. Investments in the securities market are subject to market risks. Past performance is not indicative of future results.
Links to SEBI SCORES, app stores, or other sites are provided for convenience. Partner-enabled services (such as succession coordination) are presented without partner name or pricing on this site; legal work is performed by qualified professionals.
Site design, text, and materials are owned by PrimeIdea Ventures or its licensors. You may not copy or redistribute content for commercial use without prior written permission.
We may update these terms from time to time. Continued use of the site after changes means you accept the updated terms. For complaints and grievances, use the process on Regulatory Disclosures.
Important disclaimer
Market risks apply
INH000017815
Investments in securities market are subject to market risks. PrimeIdea Ventures does not guarantee returns. Investors should verify SEBI registration independently and read all scheme-related documents carefully before investing.
View Regulatory Disclosures